Who are the suitable populations for capmatinib?

Capmatinib prevents the growth and spread of cancer cells by inhibiting MET tyrosine kinase activity. Usually this medication is indicated for those patients who do not respond to other therapies or are no longer effective.

Who are the suitable populations for capmatinib?

MET gene plays an important role in regulating cell growth, division and migration in normal cells, and this regulatory mechanism may be disrupted when exon 14 undergoes skipping changes, resulting in abnormal proliferation and metastatic potential of cancer cells, accelerating the malignant progression of NSCLC.

Capmatinib is indicated for the treatment of adult patients with certain types of metastatic non-small cell lung cancer (NSCLC) who have been genetically tested to confirm the presence of a specific molecular variant: skipping alterations in exon 14 of the mesenchymal-epithelial transition factor (MET) gene.

What are the common adverse effects of capmatinib?

Although capmatinib as a targeted therapy has shown significant efficacy in patients with non-small cell lung cancer (NSCLC) targeting MET exon 14 skipping mutations, its use has also been accompanied by a series of adverse reactions, which vary in severity and frequency in different patients.

1. Vomiting

Vomiting is the result of further development of nausea symptoms and can cause the patient to lose a lot of water and electrolytes, triggering problems such as dehydration. Vomiting caused by capmatinib needs to be treated promptly to avoid causing more physical harm to the patient. Your doctor may prescribe anti-emetic medications or adjust your treatment regimen depending on the patient's specific situation.

2. Difficulty breathing

Dyspnea is one of the adverse reactions of high concern in the treatment of capmatinib, which may affect the patient's vital signs and quality of life. Dyspnea can be caused by a variety of factors, including the direct effect of medications on lung function, edema compressing the respiratory tract, or lung infections. As soon as symptoms of dyspnea appear, patients should seek medical attention and receive professional treatment immediately.

【Warm Tips】Patients should actively communicate with their doctors about their drug feelings, physical reactions, and changes in their condition. This information is essential for doctors to adjust their treatment plan and optimize their outcomes.